Navigation Links
Novelos Therapeutics Provides Product Pipeline Update
Date:5/16/2013

tive uptake of I-131-CLR1404 in a variety of tumor types where it persists in excess of 21 days."

In parallel with the ongoing Phase 1b fourth cohort, Novelos will be evaluating a range of potential HOT Phase 2 indications and trial designs including incorporation of multiple dosing, as well as combination of HOT with external beam radiotherapy or with radiosensitizing therapeutics.

GLOW2 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for both intraoperative tumor margin illumination and non-invasive tumor imaging.  Novelos plans to file an Investigational New Drug Application (IND) for GLOW2 by the end of 2013 and, subject to additional funding, expects to generate proof-of-concept data in cancer patients by the end of 2014.  GLOW2 may address the significant unmet medical need for better definition of tumor margins and nodal involvement, potentially reducing repeat surgeries and improving patient outcomes.

"A good example of the potential utility of CLR1502 (GLOW2) is in breast cancer surgery, where 25% of patients undergoing lumpectomy require repeat resection due to incomplete removal of the primary tumor and malignant lymph nodes," said Lee Wilke , M.D., Associate Professor (CHS), Division of General Surgery, and Director Breast Center at the University of Wisconsin Carbone Cancer Center. "An imaging agent that enables improved surgical accuracy by better defining malignant tissues could significantly improve patient outcomes and rapidly impact medical practice."

Mr. Palmin further noted, "Based on positive initial LIGHT imaging results in primary and metastatic brain cancer, we believe LIGHT has potential to address a significant unmet medical need for post-treatment efficacy assessment and differentiating tumor growth from pseudoprogression in brain cancer, potentially avoiding unnecessary surgeries, biopsies and other treatments.  While LIGHT human imaging data
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novelos Therapeutics Prices $5.5 Million Public Offering
2. Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11
3. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
4. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
5. Novelos Therapeutics Closes $2 Million Private Placement
6. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
7. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
9. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
10. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
11. Novelos Therapeutics Prices $5.4 Million Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Come fall, many children, teenagers, and ... they want to be for Halloween. And, a number ... decorative contact lenses bought without a prescription. ... people purchase and wear contact lenses without a prescription. ... ® consumer survey, 17 percent of Americans have ...
(Date:9/30/2014)... Sept. 30, 2014 Chindex ... CHDX ) today announced the completion of its acquisition ... per share in cash.  Healthy Harmony is an affiliate ... and Ms. Roberta Lipson , the CEO of ... was adopted by Chindex,s stockholders at a special meeting ...
(Date:9/30/2014)... CARLOS, Calif. , Sept. 30, 2014 /PRNewswire/ ... an additional $10 million investment from current investors ... The additional financing was completed following achievement of ... lead antibody program, and represents an extension of ... closed in December 2012. With this additional financing, ...
Breaking Medicine Technology:The Spooky Truth: What You Need To Know About Contact Lens Hygiene 2The Spooky Truth: What You Need To Know About Contact Lens Hygiene 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 2Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 4Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 5Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 2Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 3Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 4
... BALTIMORE, May 5, 2011 New data presented ... Interventions (SCAI) Scientific Sessions are the first to ... within implantable cardioverter defibrillators (ICDs) to detect restricted ... disease patients outside the hospital setting. Preliminary results ...
... 5, 2011 Echo Therapeutics, Inc. (OTCBB: ECTE), a ... wireless, transdermal continuous glucose monitoring (tCGM) system and the ... the relocation of its corporate headquarters from Franklin, MA ... located in the heart of Philadelphia,s Center City Business ...
Cached Medicine Technology:New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients 2New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients 3Echo Therapeutics Expands Into New Headquarters in Philadelphia 2
(Date:9/30/2014)... 2014 Lea Blackwell, M.D., a Breast ... patients a new, more practical and comfortable option for ... mastectomies, biopsies and lumpectomy surgeries use special bras after ... seeing her patients describe the bra as scratchy, uncomfortable ... new bra in her spare time. , Ilona ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... to reach USD 8,020.1 million by 2020, according ... Inc. Growing demand for personalized medicine and theranostics, ... technologies are expected to be key factors driving ... the growing global base of geriatric population and ...
(Date:9/30/2014)... During this online virtual event, hear ... including achieving hormonal balance, relieving menopause symptoms, breast ... , The details of the virtual ... 2014, Location: Online Event, Registration: Complimentary , Visit ... Monday, October 6th, Steven F. Hotze, M.D., David ...
(Date:9/30/2014)... Oxnard, CA (PRWEB) September 30, 2014 ... the Anacapa Dental Art Institute in Oxnard and Thousand ... Bangalore today and tomorrow to provide training on full ... previous dental work, placing implants, providing cosmetic dentistry, correcting ... Dr. Jivraj said. , Dr. Jivraj, who has traveled ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... ADVISORY** , From:        Hope For ... 910.554.1505, abarnwell(at)hopeforthewarriors(dot)org , ... Celebration , Date:        Thursday, October ... Army and Navy Club, ...
Breaking Medicine News(10 mins):Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 2Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 4Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 5Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 6Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2
... American Oriental,Bioengineering, Inc. (NYSE: AOB ), ... nutraceutical products in China, today,announced that the Company ... Company will present at the CIBC World Markets ... at the Waldorf-Astoria,Hotel in New York City. Management ...
... Now Able to Submit Aetna Claims at No Cost ... Inc., a leading,healthcare technology company focused on providing innovative ... today,announced it has expanded its relationship with Aetna to ... 1, 2007. Aetna is a leading,diversified health care benefits ...
... Health Care Costs, DALLAS, Oct. 26 ... M.D., M.P.H., Cooper Aerobics Enterprises,Inc., announced today its ... Enterprises purchased Health At Work, a licensed,health, life ... Cooper Benefits,LLC. Cooper Benefits merges traditional employee ...
... WEST BERLIN, N.J., Oct. 26 EP MedSystems,(Nasdaq: EPMD ) announces the following ... 11/01/2007 @ 4:30 pm EST, Where: ... Simply log on to the web at the ... person of EP MedSystems, ...
... Jack Group, Inc.,(MattsonJack) announces the release of its ... help clients make strategic,decisions based on an in-depth ... conditions. Comorbidity Database(TM) consists of,two modules: Comorbidity Database(TM) ... and Comorbidity Database(TM) -- Med 2.0, which features ...
... Institutet have shown that hysterectomy a common operation ... the risk of urinary incontinence. Their results, which ... Lancet. , Hysterectomy is the most common gynaecological ... as a cure for benign medical problems in order ...
Cached Medicine News:Health News:American Oriental Bioengineering Announces Participation in November Healthcare Conferences 2Health News:MD On-Line Expands Relationship with Aetna for Direct Claim Submission 2Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 2Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 3Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 4Health News:Webcast Alert: EP MedSystems Announces EP MedSystems Third Quarter 2007 Earnings Conference Call Webcast 2Health News:The Mattson Jack Group, Inc. Announces the Release of the New Comorbidity Database(TM) 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: